An update from NeoGenomics ( (NEO) ) is now available.
NeoGenomics, a leader in oncology testing services, reported a robust third quarter for 2024 with a 10% rise in consolidated revenue to $168 million and a significant 305% increase in adjusted EBITDA to $13 million. The company attributes this success to strategic priorities and increased clinical services revenue, despite a 10% decline in advanced diagnostics. NeoGenomics also revised its full-year guidance upwards, reflecting confidence in sustained growth and profitability.
For detailed information about NEO stock, go to TipRanks’ Stock Analysis page.
